5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb study

5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb study

J Randolph Hecht,1 Edith P Mitchell,2 Takayuki Yoshino,3 Manfred Welslau,4 Xun Lin,5 Edna Chow Maneval,6 Jolanda Paolini,7 Maria Jose Lechuga,7 Albrecht Kretzschmar8  1David Geffen School of Medicine at UCLA, Santa Monica, CA, 2Kimmel Cancer Center of Thomas Jefferson University, Philadelph...

Full description

Bibliographic Details
Main Authors: Hecht JR, Mitchell EP, Yoshino T, Welslau M, Lin X, Chow Maneval E, Paolini J, Lechuga MJ, Kretzschmar A
Format: Article
Language:English
Published: Dove Medical Press 2015-06-01
Series:Cancer Management and Research
Online Access:http://www.dovepress.com/5-fluorouracil-leucovorin-and-oxaliplatin-mfolfox6-plus-sunitinib-or-b-peer-reviewed-article-CMAR

Internet

http://www.dovepress.com/5-fluorouracil-leucovorin-and-oxaliplatin-mfolfox6-plus-sunitinib-or-b-peer-reviewed-article-CMAR

Similar Items